Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 1
1976 3
1977 3
1978 1
1979 2
1981 2
1982 3
1983 6
1984 3
1985 7
1986 5
1987 7
1988 9
1989 14
1990 6
1991 15
1992 10
1993 9
1994 10
1995 6
1996 11
1997 7
1998 6
1999 8
2000 10
2001 7
2002 6
2003 4
2004 9
2005 4
2006 2
2007 4
2008 9
2009 8
2010 14
2011 10
2012 13
2013 12
2014 10
2015 13
2016 17
2017 11
2018 13
2019 17
2020 18
2021 16
2022 10
2023 16
2024 18
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Results by year

Filters applied: . Clear all
Page 1
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
METHODS: We did a registrational, multicentre, open-label, crossover, phase 3 trial of individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia and individuals with acute myeloid leukaemia, enrolled as separate cohorts; results for only …
METHODS: We did a registrational, multicentre, open-label, crossover, phase 3 trial of individuals with myelodysplastic syndromes or chro …
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Bazinet A, et al. Lancet Haematol. 2022 Oct;9(10):e756-e765. doi: 10.1016/S2352-3026(22)00216-2. Epub 2022 Sep 2. Lancet Haematol. 2022. PMID: 36063832 Clinical Trial.
We enrolled patients (18 years) with treatment-naive or relapsed or refractory high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia and bone marrow blasts of more than 5%. No specific Eastern Cooperative Oncology Group status restriction wa …
We enrolled patients (18 years) with treatment-naive or relapsed or refractory high-risk myelodysplastic syndromes or chronic myel …
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review.
Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Patnaik MM, et al. Br J Haematol. 2014 May;165(3):273-86. doi: 10.1111/bjh.12756. Epub 2014 Jan 28. Br J Haematol. 2014. PMID: 24467717 Review.
Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder with myelodysplastic and myeloproliferative overlap features, and an inherent tendency to transform to acute myeloid leukaemia. ...
Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder with myelodysplastic and myelopro …
Leukaemia cutis as a specific skin involvement in chronic myelomonocytic leukaemia and review of the literature: Acknowledgments.
Qiao Y, Jian J, Deng L, Tian H, Liu B. Qiao Y, et al. Transl Cancer Res. 2020 Aug;9(8):4988-4998. doi: 10.21037/tcr-19-2882. Transl Cancer Res. 2020. PMID: 35117861 Free PMC article. Review.
The skin involvement of myeloid leukaemia is conventionally divided into specific malignant lesions and non-specific benign lesions, and these categories are also applicable in chronic myelomonocytic leukaemia (CMML). According to the 2016 World Health Organi …
The skin involvement of myeloid leukaemia is conventionally divided into specific malignant lesions and non-specific benign lesions, and the …
Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL, Martiat P. Michaux JL, et al. Leuk Lymphoma. 1993 Jan;9(1-2):35-41. doi: 10.3109/10428199309148501. Leuk Lymphoma. 1993. PMID: 8477199 Review.
Chronic myelomonocytic leukaemia (CMML), a disorder belonging to the group of myelodysplastic syndromes, has a number of peculiar features which raise the question as to whether it should be considered a distinct entity in its own right. ...
Chronic myelomonocytic leukaemia (CMML), a disorder belonging to the group of myelodysplastic syndromes, has a number o …
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Br J Haematol. 2023 Nov;203(4):581-592. doi: 10.1111/bjh.19060. Epub 2023 Aug 22. Br J Haematol. 2023. PMID: 37608562
Chronic myelomonocytic leukaemia (CMML) is a haematological disorder with high risk of transformation to acute myeloid leukaemia (AML). ...
Chronic myelomonocytic leukaemia (CMML) is a haematological disorder with high risk of transformation to acute myeloid …
Chronic myelomonocytic leukaemia causing orbital inflammation.
McGrath R, Fay M, McAnena L. McGrath R, et al. BMJ Case Rep. 2024 Oct 30;17(10):e258203. doi: 10.1136/bcr-2023-258203. BMJ Case Rep. 2024. PMID: 39477459
We present a case of acute-onset orbital inflammation with rapidly progressive proptosis, episcleral venous stasis with raised intraocular pressure and loss of vision in a patient with a recent diagnosis of chronic myelomonocytic leukaemia (CMML). The patient …
We present a case of acute-onset orbital inflammation with rapidly progressive proptosis, episcleral venous stasis with raised intraocular p …
Chronic myelomonocytic leukaemia.
Geary CG, Catovsky D, Wiltshaw E, Milner GR, Scholes MC, Van Noorden S, Wadsworth LD, Muldal S, MacIver JE, Galton DA. Geary CG, et al. Br J Haematol. 1975 Jul;30(3):289-302. doi: 10.1111/j.1365-2141.1975.tb00544.x. Br J Haematol. 1975. PMID: 1059474
401 results